Marianne De Backer sold $141k of VIR
Chief Executive Officer at Vir Biotechnology, Inc.. 14,762 shares at an average of $9.53, traded Feb 24, 2026, filed Feb 26, 2026.
Score components
- +25RoleCEO
- +11Trade size$141k at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.9%, 3m +2.5%, 6m +21.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-012390, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -14,762 | $9.53 | $141k | 1,020,704 | Feb 26, 2026 |
Related signals
Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Vir Biotechnology, Inc. | Janet Napolitano director | $30k 3,200 shares | -13% | |
| 3Weak | Vir Biotechnology, Inc. | Brent Sabatini SVP, Chief Accounting Officer | $3,582 379 shares | -1% | |
| 7Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $221k 22,000 shares | -2% | |
| 40Moderate | Vir Biotechnology, Inc. | Marianne De Backer President and CEO | $664k 72,559 shares | -7% | |
| 22Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $200k 22,000 shares | -2% | |
| 23Weak | Vir Biotechnology, Inc. | Brent Sabatini SVP, Chief Accounting Officer | $70k 7,711 shares | -11% | |
| 22Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $209k 22,000 shares | -2% | |
| 16Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $34k 3,505 shares | -2% | |
| 17Weak | Vir Biotechnology, Inc. | Jason O'Byrne EVP & Chief Financial Officer | $16k 1,634 shares | -1% | |
| 11Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $413k 42,377 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.